Holen Sie sich die Stockscreener-App
20.57
0.63%
-0.13
Handel nachbörslich:
20.50
-0.07
-0.34%
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed? - Yahoo! Finance Canada
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains - Yahoo Finance
Denali Rises 11.8% Over the Past Month: Should You Buy, Sell, or Keep the Stock? - Bitget
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock? - TradingView
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
A Look At Denali Therapeutics (DNLI) Valuation After Wider Losses And New US$200 Million Shelf Registration - Sahm
Denali ‘Moving In A Positive Direction’ With FDA Toward Hunter Drug Action Date - Citeline News & Insights
DNLI: Awaiting FDA decision on a novel Hunter syndrome therapy, with broad pipeline and commercial momentum - TradingView
Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.1%Should You Buy? - MarketBeat
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
How Denali Therapeutics Inc. stock reacts to global recession fearsPortfolio Risk Report & Stock Market Timing Techniques - Naître et grandir
DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - MSN
(DNLI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Denali Therapeutics (DNLI) Is Down 8.0% After Wider Losses And New Shelf Filing Has The Bull Case Changed? - simplywall.st
HC Wainwright Issues Positive Forecast for DNLI Earnings - MarketBeat
Rafferty Asset Management LLC Buys 60,624 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Market Wrap: Can Denali Therapeutics Inc scale operations efficientlyJuly 2025 Earnings & Verified Chart Pattern Signals - baoquankhu1.vn
Bank of America Securities Remains a Buy on Denali Therapeutics (DNLI) - The Globe and Mail
DNLI: Pivotal 2026 ahead with FDA review, new launches, and major clinical milestones in rare diseases - TradingView
TD Asset Management Inc Trims Stock Position in Denali Therapeutics Inc. $DNLI - MarketBeat
Fisher Asset Management LLC Increases Holdings in Denali Therapeutics Inc. $DNLI - MarketBeat
Assessing Denali Therapeutics (DNLI) Valuation After Wider Losses And New Shelf Registration - Sahm
Denali Therapeutics Inc. (DNLI) Investor Outlook: Analyzing The 56.80% Potential Upside - DirectorsTalk Interviews
Vanguard Group Inc. Purchases 182,183 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Jefferies reiterates Denali stock Buy rating on gene therapy outlook By Investing.com - Investing.com Canada
Jefferies reiterates Denali stock Buy rating on gene therapy outlook - Investing.com India
BTIG Research Increases Denali Therapeutics (NASDAQ:DNLI) Price Target to $36.00 - MarketBeat
Denali Therapeutics (DNLI): BTIG Raises Price Target to $36.00 | - GuruFocus
Denali Therapeutics Inc. Trade Ideas — GETTEX:4DN - TradingView
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - National Today
Does Denali Therapeutics' (DNLI) Widening Quarterly Loss Reframe Its Pipeline-First Investment Narrative? - simplywall.st
Denali Therapeutics (NASDAQ:DNLI) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Denali Therapeutics Q4 net loss deepens - TradingView
Denali Therapeutics (DNLI) widens 2025 loss but fortifies cash for key 2026 drug milestones - Stock Titan
BRIEF-Denali Therapeutics Q4 Operating Expenses USD 137.365 Million - TradingView
Hunter syndrome drug nears April FDA call as Denali raises $475M - Stock Titan
Volume Recap: Is Denali Therapeutics Inc. a turnaround storyMarket Weekly Review & Weekly Chart Analysis and Guides - baoquankhu1.vn
Denali Therapeutics Inc. (DNLI) Stock Analysis: Strong Buy Ratings Signal a 57% Potential Upside - DirectorsTalk Interviews
Wolfe Research initiates Denali Therapeutics stock with Peerperform - Investing.com
Wolfe Research initiates Denali Therapeutics stock with Peerperform By Investing.com - Investing.com UK
Wolfe Research Initiates Coverage of Denali Therapeutics (DNLI) with Peer Perform Recommendation - Nasdaq
(DNLI) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Buyout Rumor: Is Denali Therapeutics Inc forming a bullish divergenceJuly 2025 Action & Accurate Intraday Trade Tips - baoquankhu1.vn
Aberdeen Group plc Buys 210,835 Shares of Denali Therapeutics Inc. $DNLI - Defense World
Denali Therapeutics (DNLI) Expected to Announce Earnings on Thursday - MarketBeat
Denali Therapeutics Inc. $DNLI Shares Sold by Thrivent Financial for Lutherans - Defense World
Pharma could be on the cusp of finally breaking the blood-brain barrier - PharmaVoice
Big Picture: Why is Denali Therapeutics Inc stock going downJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
How Denali Therapeutics Inc. stock performs in rate cut cyclesJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - mfd.ru
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
(DNLI) Risk Channels and Responsive Allocation - Stock Traders Daily
Ideas Watch: Is Denali Therapeutics Inc. a turnaround storyEarnings Growth Summary & Smart Money Movement Tracker - baoquankhu1.vn
Assessing Denali Therapeutics (DNLI) Valuation After WORLDSymposium Clinical Updates And Regulatory Progress - Sahm
Principal Financial Group Inc. Purchases 198,207 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics (DNLI) Gets a Buy from Wedbush - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Haemonetics (HAE) and Denali Therapeutics (DNLI) - The Globe and Mail
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):